Taiho Ventures
Now investing · Fund III

We back the
quiet revolutions
in human health.

Taiho Ventures is a $400M corporate fund — strategic, patient, and backed by sixty years of Japanese pharmaceutical R&D.

Oncology✦Immunology✦Rare disease✦Platform tech✦Spin-outs✦Cell & gene✦First-in-class✦Allergy✦Bone & muscle✦Oncology✦Immunology✦Rare disease✦Platform tech✦Spin-outs✦Cell & gene✦First-in-class✦Allergy✦Bone & muscle✦

What we
look for.

§ Investment Criteria
01

Drug Discovery

First-in-class chemistry and new biology — small molecules, biologics, gene & cell therapy.

02

Platform Tech

Foundational platforms that compound across many programs and shorten the path to clinic.

03

Spin-outs

Strategic carve-outs from the Taiho pipeline, ready to chart their own course with our backing.

04

Devices & Dx

Opportunistic — diagnostics, devices, digital health adjacent to our therapeutic areas.

Therapeutic areas
Oncology · Immunology · Allergy · Bone · Muscle · Rare
Modality
Small molecules · Biologics · Gene & Cell
Stage
Research → Pre-IND · IND → PoC (opportunistic)
§ Portfolio · 24 active

The companies
we walk with.

We hold for the long arc. Our companies receive operating support across discovery, regulatory, and global commercial — not just a check.
P/001
Cullinan
Onc · Series B
P/002
Orna Therapeutics
Imm · Series C
P/003
Halda
Plat · Series A
P/004
Magnet Bio
Onc · Series A
P/005
Werewolf Tx
Imm · Series B
P/006
Harpoon Tx
Onc · Series C
P/007
NextCure
Onc · Series D
P/008
ORIC Pharma
Onc · Series E
P/009
Anavo Therapeutics
Imm · Series A
P/010
Dren Bio
Plat · Series B
P/011
Storm Tx
Onc · Series B
P/012
Theo
Plat · Series A
P/013
Light Horse
Plat · Series A
P/014
Cellvie
Onc · Series B
P/015
Transition Bio
Plat · Series C
P/016
Vertero
Onc · Series A
§ Get in touch

Have you started a
company that matters?

We respond to every pitch within two weeks. No warm intro required — just a deck and a hypothesis.